Drug Profile
Sonepcizumab - Lpath
Alternative Names: ASONEP; iSONEP; LT-1009; Sonepcizumab/LT1009; Sphingomab™Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Lpath
- Developer Lpath; Pfizer
- Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Wet age-related macular degeneration
- No development reported Diabetic retinopathy; Eye disorders; Inflammation; Multiple sclerosis
- Discontinued Heart failure; Renal cell carcinoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (Ophthalmic, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)